PNC Financial Services Group
LXEO icon

PNC Financial Services Group’s Lexeo Therapeutics LXEO Stock Holding History

PNC Financial Services Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09K Sell
234
-271
-54% -$1.47K ﹤0.01% 4821
2026
Q1 		$2.9K Buy
505
+18
+4% +$128 ﹤0.01% 4469
2025
Q4 		$4.84K Sell
487
-186
-28% -$1.7K ﹤0.01% 4245
2025
Q3 		$4.47K Buy
+673
New +$3.25K ﹤0.01% 4246

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PNC Financial Services Group's LXEO Position: Q2 2026 in Review

PNC Financial Services Group reduced its Lexeo Therapeutics (LXEO) stake by 54% in Q2 2026, selling an estimated $1.47K and leaving 234 shares worth $1.09K. The position accounts for ﹤0.01% of the portfolio, ranked #4821.

PNC Financial Services Group first reported a position in LXEO in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.84K in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • PNC Financial Services Group held 234 shares of Lexeo Therapeutics worth $1.09K as of Q2 2026.
  • PNC Financial Services Group sold 271 Lexeo Therapeutics shares in Q2 2026, an estimated $1.47K.
  • Lexeo Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4821 holding.
  • PNC Financial Services Group first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • PNC Financial Services Group's Lexeo Therapeutics position peaked at $4.84K in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.